Johnson & Johnson $JNJ Shares Sold by Gradient Capital Advisors LLC

Gradient Capital Advisors LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 5,374 shares of the company’s stock after selling 242 shares during the period. Gradient Capital Advisors LLC’s holdings in Johnson & Johnson were worth $821,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of JNJ. Highline Wealth Partners LLC increased its position in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the first quarter worth approximately $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the first quarter worth approximately $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson during the 1st quarter worth $52,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on JNJ shares. Bank of America raised their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Thursday, July 17th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Finally, Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $181.40.

Johnson & Johnson Price Performance

JNJ stock opened at $179.69 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a 50-day moving average price of $174.41 and a 200 day moving average price of $162.06. The stock has a market cap of $432.75 billion, a PE ratio of 19.22, a P/E/G ratio of 2.29 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the business posted $2.82 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.